Swedish Orphan Biovitrum Retained Earnings (Accumulated Deficit) 2019-2025 | BIOVF

Swedish Orphan Biovitrum retained earnings (accumulated deficit) for the quarter ending June 30, 2025 were $2.426B, a 36.23% increase year-over-year.

  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2024 were $2.074B, a 21.82% increase from 2023.
  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2023 were $1.703B, a 8.79% increase from 2022.
  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2022 were $1.565B, a 2.03% increase from 2021.

Swedish Orphan Biovitrum Retained Earnings (Accumulated Deficit) 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2024 were $2.074B, a 21.82% increase from 2023.
  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2023 were $1.703B, a 8.79% increase from 2022.
  • Swedish Orphan Biovitrum retained earnings (accumulated deficit) for 2022 were $1.565B, a 2.03% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$225.3B
Amgen (AMGN)$164.8B
Gilead Sciences (GILD)$144.5B
Vertex Pharmaceuticals (VRTX)$120.6B
Bristol Myers Squibb (BMY)$98.6B
CSL (CSLLY)$85.4B
GSK (GSK)$77.5B
Regeneron Pharmaceuticals (REGN)$60.8B
Alnylam Pharmaceuticals (ALNY)$42.9B
Argenex SE (ARGX)$36.2B
BioNTech SE (BNTX)$27.7B
Royalty Pharma (RPRX)$20.6B
Insmed (INSM)$19.7B
Biogen (BIIB)$19.3B
Illumina (ILMN)$17.3B
Genmab (GMAB)$15B
Genmab (GNMSF)$15B
Incyte (INCY)$13.6B
Moderna (MRNA)$13.2B
Exelixis (EXEL)$12.4B
QIAGEN (QGEN)$11.5B
BioMarin Pharmaceutical (BMRN)$11.3B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9.2B
Exact Sciences (EXAS)$9.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Legend Biotech (LEGN)$8B
Roivant Sciences (ROIV)$7.9B
Regencell Bioscience Holdings (RGC)$7.4B